Prospective Phase I/II Study to Investigate the Feasibility, Safety and Efficacy of IL-15 Activated Cytokine Induced Killer (CIK) Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After Allogeneic SCT



This multicentre phase I / II feasibility study aims to investigate the safety and effectiveness of treatment with IL-15 activated cytokine-induced killer cells (CIK). Patients with acute leukemia or myelodysplastic syndrome after allogeneic stem cell transplantation can participate in this study. Infusions of the CIK cells are given at 4-6 week intervals.

Main inclusion criteria

  • Acute leukemia and MDS patients with molecular or cytogenetic relapse in peripheral blood (PB) or bone marrow (BM) samples obtained during monitoring for relapse after allogeneic SCT


University Hospital Frankfurt

Diese Webseite verwendet Cookies. Durch die Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Datenschutzinformationen